Create an Account User ID Password    
Help   Forgot Password  
Date/TimeSessionPaperNumber
Oct 29
2:30 PM-3:45 PM
Memantine for the Prevention of Cognitive Dysfunction in Patients Receiving Whole-brain Radiation Therapy (WBRT): First Report of RTOG 0614, a Placebo-controlled, Double-blind, Randomized Trial 1
Oct 29
2:30 PM-3:45 PM
Radiation Therapy Protocol Deviations are Associated With Inferior Clinical Outcomes: A Meta-analysis of Cooperative Group Clinical Trials 2
Oct 29
2:30 PM-3:45 PM
Results of a Prospective Randomized Double-blind Placebo Controlled Trial Evaluating the Use Prophylactic Sildenafil Citrate During Radiation Therapy in the Treatment of Prostate Cancer 3
Oct 29
2:30 PM-3:45 PM
Patient Beliefs About Palliative Radiation Therapy (RT) in Incurable Lung Cancer 4
Oct 28
1:45 PM-3:15 PM
Is Stereotactic Body Radiation Therapy (SBRT) an Attractive Option for Unresectable Liver Metastases? Early Results From a Phase II Trial 5
Oct 28
1:45 PM-3:15 PM
Prospective Evaluation of Dual-energy Imaging in Patients Undergoing Image Guided Radiation Therapy for Lung Cancer: Initial Clinical Results 6
Oct 28
1:45 PM-3:15 PM
Radium-223 Chloride Safety and Use of External Beam Radiation Therapy (EBRT) in the Phase III Randomized Trial (ALSYMPCA) in Patients With Castration-resistant Prostate Cancer (CRPC) and Bone Metastases 7
Oct 28
1:45 PM-3:15 PM
Final Analysis of Intergroup Randomized Phase III Study of Androgen Deprivation Therapy (ADT) + Radiation Therapy (RT) in Locally Advanced Prostate Cancer (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110; NCT00002633) 8
Oct 28
1:45 PM-3:15 PM
A Revised RTOG Recursive Partitioning Analysis (RPA) Model for Glioblastoma Based Upon Multi-platform Biomarker Profiles 9
Oct 28
1:45 PM-3:15 PM
IDH Status Predicts Benefit From PCV+RT in Anaplastic Oligodendroglioma (RTOG 9402) 10
Oct 28
1:45 PM-3:15 PM
Low Risk Breast Ductal Carcinoma in Situ (DCIS): Results From the RTOG Phase III 9804 Trial 11
Oct 28
1:45 PM-3:15 PM
Patterns of Relapse From a Phase III Study of Response-based Therapy for Intermediate-risk Hodgkin lymphoma (AHOD0031): A Report From the Children’s Oncology Group 12
Oct 28
1:45 PM-3:15 PM
RTOG 90-03: Final Report 13
Oct 28
1:45 PM-3:15 PM
Radiation of Potential Local Cancer Stem Cell Niches Improves Survival of Patients With Glioblastoma Multiforme. 14
Oct 28
1:45 PM-3:15 PM
Impact of Concurrent and Adjuvant Bevacizumab on the Risk of Radiation Necrosis Following Radiosurgery for Recurrent Glioma 15
Oct 28
1:45 PM-3:15 PM
An American Brain Tumor Consortium (ABTC) Phase I Trial of Veliparib (ABT-888), Temozolomide (TMZ), and Concurrent Radiation Therapy (RT) for Newly Diagnosed Glioblastoma Multiforme (GBM): Need for Modification to Approach for Combining These Therapies 16
Oct 28
1:45 PM-3:15 PM
A Phase I/II Clinical Trial of Dose Escalation on Biological Target Volume With Intensity Modulated Radiation Therapy: The Long-term Results 17
Oct 28
1:45 PM-3:15 PM
Increased Radiation Dose to the SVZ Improves Survival in Patients With GBM 18
Oct 28
1:45 PM-3:15 PM
A Novel Metric of Patient-specific Response to Treatment for Glioblastoma Discriminates Patients With Pseudo-progression 19
Oct 28
1:45 PM-3:15 PM
Novel Role of O6-methylguanine Methyltransferase in the Invasion/proliferation Dichotomy in Glioblastoma. 20
Oct 28
1:45 PM-3:15 PM
Hypo-fractionated IMRT With TMZ For GBMs -tailor-made Setting Of Treatment Doses Owing To MGMT-methylation Status- 21
Oct 28
1:45 PM-3:15 PM
Phase II Trial of Palliative Radiotherapy for Symptomatic Hepatocellular Carcinoma and Liver Metastases 22
Oct 28
1:45 PM-3:15 PM
Phase I-II trial of Stereotactic Body Radiotherapy (SBRT) in Patients with Hepatocellular Carcinoma, Child-Pugh’s Class (CPC) A and B: Interim Analysis of Treatment Variables affecting Toxicity and Outcome 23
Oct 28
1:45 PM-3:15 PM
Phase I Study of Sorafenib and SBRT for Advanced Hepatocellular Carcinoma 24
Oct 28
1:45 PM-3:15 PM
Outcomes of Stereotactic Radiotherapy (SRT) for Primary and Metastatic Liver Tumors with 3-D CT and Single Photon Emission Computed Tomography (3D-CT/SPECT) Treatment Planning. 25
Prism Technologies Inc.